Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CTRC | Q99895 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.41 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29144919 | 0.79 | ERCC1 (0.46) | NOTUMSMN1; SMN2KDM4EGAAMAPT | |
| SCHEMBL7271565 | 0.79 | GCGR (0.41) | MAPTLMNACDK5CLK4NPY5R | |
| SCHEMBL5210215 | 0.77 | BRD4 (0.53) | NOTUMKDM4EGAAHPGDALDH1A1 | |
| SCHEMBL9956357 | 0.77 | NOTUM (0.47) | NOTUMCLK4NPY5RNPC1RAB9A | |
| SCHEMBL9954744 | 0.77 | ALDH1A1 (0.49) | NOTUMSMN1; SMN2KDM4EMAPTHPGD | |
| SCHEMBL12309805 | 0.75 | NOTUM (0.46) | NOTUMSMN1; SMN2KDM4EMAPTTDP1 | |
| SCHEMBL1361621 | 0.75 | NOTUM (0.46) | NOTUMNPY5RSCN2ARAB9A | |
| SCHEMBL905288 | 0.71 | LMNA (0.50) | SMN1; SMN2KDM4EGAAMAPTTDP1 | |
| SCHEMBL1361865 | 0.71 | MEN1 (0.51) | NOTUMKDM4EGAAMAPTPLA2G10 | |
| SCHEMBL1523603 | 0.71 | TAS2R38 (0.47) | NOTUMSMN1; SMN2KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 375 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115010677-B | Preparation method of 4-phenyl-2 (3H) -oxazolone | 扬州市普林斯医药科技有限公司 | 2024-05-03 | — | — | CN | claimed |
| CN-115010677-A | Preparation method of 4-phenyl-2 (3H) -oxazolone | 扬州市普林斯医药科技有限公司 | 2022-09-06 | — | — | CN | claimed |
| CN-109320554-B | Novel method for synthesizing practical acetaminoacrylate compound | 浙江海翔药业股份有限公司 | 2021-04-27 | — | — | CN | claimed |
| US-7193079-B1 | Preparation of hymenialdisine derivatives and use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2007-03-20 | — | — | US | claimed |
| US-20070049575-A1 | PREPARATION OF HYMENIALDISINE DERIVATIVES AND USE THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2007-03-01 | — | — | US | claimed |
| WO-2004103958-A2 | PREPARATION OF HYMENIALDISINE DERIVATIVES AND USE THEREOF | MICHIGAN STATE UNIVERSITY (US) | 2004-12-02 | — | — | WO | claimed |
| US-20040235820-A1 | Preparation of hymenialdisine derivatives and use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2004-11-25 | — | — | US | claimed |
| US-6461810-B1 | DIAGNOSING GENETIC DISORDERS; GENETIC ENGINEERING | PRINCETON UNIVERSITY | 2002-10-08 | — | — | US | claimed |
| WO-1999024622-A1 | TRIPLEX IN-SITU HYBRIDIZATION | PRINCETON UNIVERSITY (US) | 1999-05-20 | — | — | WO | claimed |
| EP-0832286-A4 | MODIFIED NUCLEOTIDES FOR NUCLEIC ACID LABELING | ONCOR INC (US) | 1998-11-04 | — | — | EP | claimed |
| EP-0832286-A1 | MODIFIED NUCLEOTIDES FOR NUCLEIC ACID LABELING | ONCOR, INC. (US) | 1998-04-01 | — | — | EP | claimed |
| US-5728526-A | ANALYZING, HYBRIDIZING AND DETECTION | ONCOR, INC. (US) | 1998-03-17 | — | — | US | claimed |
| US-5684142-A | Modified nucleotides for nucleic acid labeling | ONCOR, INC. (US) | 1997-11-04 | — | — | US | claimed |
| WO-1996041006-A1 | MODIFIED NUCLEOTIDES FOR NUCLEIC ACID LABELING | ONCOR, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0223177-B1 | CARDIOTONIC PHENYL OXAZOLONES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-08-19 | — | — | EP | claimed |
| US-4866085-A | Cardiotonic phenyl oxazolones | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-12 | — | — | US | claimed |
| US-4728661-A | Cardiotonic phenyl oxazolones | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-03-01 | — | — | US | claimed |
| EP-0223177-A1 | Cardiotonic phenyl oxazolones | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-05-27 | — | — | EP | claimed |
| US-20250333533-A1 | MACROPINOCYTOSING HUMAN ANTI-CD46 ANTIBODIES AND TARGETED CANCER THERAPEUTICS | UNIV CALIFORNIA (US) | 2025-10-30 | — | — | US | disclosed |
| US-4026700-A | Charged particle modulator device and improved imaging methods for use thereof | ADDRESSOGRAPH MULTIGRAPH CORPORATION (US) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235820-A1 | Preparation of hymenialdisine derivatives and use thereof | NFKBIA, IKBKG, GSK3B | NOTUM 1867/4885SMN1; SMN2 4429/4885KDM4E 1594/4885 |
| US-20070049575-A1 | PREPARATION OF HYMENIALDISINE DERIVATIVES AND USE THEREOF | IDO2, CHEK2, NFKBIA | NOTUM 1949/4885SMN1; SMN2 4454/4885KDM4E 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.